annual meeting program - American Society of Clinical Oncology

MONDAY
Monday, June 7, 2010
3:00 PM - 6:00 PM
ORAL ABSTRACT SESSION
Gastrointestinal (Noncolorectal) Cancer
Location: E Hall D1
CME credit: 3
Track(s): Gastrointestinal (Noncolorectal) Cancer
Theodore S. Hong, MD—Co-Chair
Massachusetts General Hospital
Alexandria T. Phan, MD—Co-Chair
University of Texas M. D. Anderson Cancer Center
3:00 PM Effect of preoperative concurrent survival of patients with resectable
esophageal or esophagogastric junction cancer: Results from a multicenter
randomized phase III study. (Abstract #4004)
A. V. Gaast, P. van Hagen, M. Hulshof, D. Richel, M. I. van Berge Henegouwen,
G. A. Nieuwenhuijzen, J. T. Plukker, J. J. Bonenkamp, E. W. Steyerberg,
H. W. Tilanus, CROSS study group
3:15 PM Surgery alone versus chemoradiotherapy followed by surgery for localized
esophageal cancer: Analysis of a randomized controlled phase III trial FFCD
9901. (Abstract #4005)
C. Mariette, J. F. Seitz, E. Maillard, F. Mornex, P. a. Thomas, J. Raoul, V. Boige,
D. Pezet, C. Genet, L. Bedenne, Federation Francaise de Cancerologie Digestive
3:30 PM CALGB 80403/ECOG 1206: A randomized phase II study of three standard
chemotherapy regimens (ECF, IC, FOLFOX) plus cetuximab in metastatic
esophageal and GE junction cancer. (Abstract #4006)
P. C. Enzinger, B. Burtness, D. Hollis, D. Niedzwiecki, D. Ilson, A. B. Benson,
R. J. Mayer, R. M. Goldberg
3:45 PM AVAGAST: A randomized, double-blind, placebo-controlled, phase III study
of first-line capecitabine and cisplatin plus bevacizumab or placebo in
patients with advanced gastric cancer (AGC). (Abstract #LBA4007)
Y. Kang, A. Ohtsu, E. Van Cutsem, S. Y. Rha, A. Sawaki, S. Park, H. Lim, J. Wu,
B. Langer, M. A. Shah
Discussion
4:00 PM Charles Fuchs, MD (Abstracts #4004–LBA4007)
Dana-Farber Cancer Institute
4:15 PM Phase III study of oxaliplatin plus 5-fluorouracil/leucovorin (FOLFOX4)
versus doxorubicin as palliative systemic chemotherapy in advanced HCC in
Asian patients. (Abstract #4008)
S. Qin, Y. Bai, S. Ye, J. Fan, H. Lim, J. Y. Cho, S. Thongprasert, Y. Chao, K. Rau,
Y. Sun
4:30 PM Effect of IFN therapy and amino acid substitutions in the hepatitis C virus
(HCV) core region on hepatocarcinogenesis in HCV-related cirrhotic patients.
(Abstract #4009)
M. Hirakawa, K. Ikeda, N. Akuta, Y. Kawamura, T. Hosaka, M. Kobayashi,
F. Suzuki, Y. Suzuki, Y. Arase, H. Kumada
Discussion
4:45 PM Timothy Pawlik, MD, MPH (Abstracts #4008–4009)
The Johns Hopkins University
5:00 PM Randomized phase III trial comparing FOLFIRINOX (F: 5FU/leucovorin [LV],
irinotecan [I], and oxaliplatin [O]) versus gemcitabine (G) as first-line
treatment for metastatic pancreatic adenocarcinoma (MPA): Preplanned
interim analysis results of the PRODIGE 4/ACCORD 11 trial. (Abstract #4010)
T. Conroy, F. Desseigne, M. Ychou, M. Ducreux, O. Bouche, R. Guimbaud,
Y. Becouarn, C. Montoto-Grillot, S. Gourgou-Bourgade, A. Adenis, FNCLCC-FFCD
PRODIGE Group
408